Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009882 | 0.86 | CA2 (0.38) | HTR6KMT2AKDM4EALDH1A1 | |
| SCHEMBL354323 | 0.84 | RPS6KB1 (0.42) | DUTHDAC4HDAC7HDAC5HTR6 | |
| SCHEMBL6009845 | 0.83 | ADRA2C (0.43) | HTR6GPR139KMT2ACASRALDH1A1 | |
| SCHEMBL6009898 | 0.83 | HTT (0.43) | HTR6KMT2AKDM4EALDH1A1 | |
| SCHEMBL6009922 | 0.83 | HTT (0.43) | HTR6KMT2AKDM4EALDH1A1 | |
| SCHEMBL6009893 | 0.83 | HTT (0.43) | HTR6KMT2AKDM4EALDH1A1 | |
| SCHEMBL14099965 | 0.83 | CYP3A4 (0.53) | SCN8AKMT2ACASRKDM4EALDH1A1 | |
| SCHEMBL10231050 | 0.83 | CYP3A4 (0.53) | SCN8AKMT2ACASRKDM4EALDH1A1 | |
| SCHEMBL10231054 | 0.83 | CYP3A4 (0.53) | SCN8AKMT2ACASRKDM4EALDH1A1 | |
| SCHEMBL353007 | 0.82 | CASR (0.57) | HTR6KMT2ACASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | DUT 1567/4885HDAC4 4412/4885HDAC7 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.